Ultragenyx Pharmaceutical (RARE) Stock Forecast, Price & News

Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions

Is Ultragenyx Pharmaceutical a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ultragenyx Pharmaceutical stock.
View analyst ratings for Ultragenyx Pharmaceutical or view top-rated stocks.

When is Ultragenyx Pharmaceutical's next earnings date?

Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Monday, August 1st 2022.
View our earnings forecast for Ultragenyx Pharmaceutical.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced its quarterly earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($2.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.78) by $0.41. The biopharmaceutical company had revenue of $79.94 million for the quarter, compared to analyst estimates of $84.25 million. Ultragenyx Pharmaceutical had a negative net margin of 141.65% and a negative trailing twelve-month return on equity of 49.18%. The business's revenue for the quarter was down 19.6% compared to the same quarter last year. During the same period last year, the firm posted ($2.03) earnings per share.
View Ultragenyx Pharmaceutical's earnings history.

What price target have analysts set for RARE?

11 brokerages have issued twelve-month target prices for Ultragenyx Pharmaceutical's shares. Their forecasts range from $73.00 to $162.00. On average, they expect Ultragenyx Pharmaceutical's stock price to reach $112.15 in the next year. This suggests a possible upside of 131.0% from the stock's current price.
View analysts' price targets for Ultragenyx Pharmaceutical or view top-rated stocks among Wall Street analysts.

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the following people:

• Dr. Emil D. Kakkis M.D., Ph.D., Pres, CEO & Director (Age 62, Pay $1.43M)
• Ms. Mardi C. Dier, Exec. VP & CFO (Age 58, Pay $216.35k) (LinkedIn Profile)
• Mr. John Richard Pinion II, Chief Quality Operations Officer & Exec. VP of Translational Sciences (Age 56, Pay $747.2k) (LinkedIn Profile)
• Dr. Camille L. Bedrosian M.D., Chief Medical Officer & Exec. VP (Age 69, Pay $844.42k) (LinkedIn Profile)
• Mr. Erik Harris, Exec. VP & Chief Commercial Officer (Age 51, Pay $793.86k) (LinkedIn Profile)
• Mr. Theodore A. Huizenga, Sr. VP, Corp. Controller & Principal Accounting Officer (Age 51) (LinkedIn Profile)
• Mr. Dennis Karl Huang, Chief Technical Operations Officer & Exec. VP (Age 57) (LinkedIn Profile)
• Ms. Danielle Keatley, Sr. Director of Investor Relations & Corp. Communications
• Ms. Karah Herdman Parschauer J.D., Gen. Counsel & Exec. VP (Age 44) (LinkedIn Profile)
• Mr. Ernie W. Meyer, Chief HR Officer & Exec. VP (Age 58)

What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO?

41 employees have rated Ultragenyx Pharmaceutical CEO Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among Ultragenyx Pharmaceutical's employees.

Who are some of Ultragenyx Pharmaceutical's key competitors?

Some companies that are related to Ultragenyx Pharmaceutical include Elanco Animal Health (ELAN), Biohaven Pharmaceutical (BHVN), Organon & Co. (OGN), Teva Pharmaceutical Industries (TEVA), Jazz Pharmaceuticals (JAZZ), Dr. Reddy's Laboratories (RDY), Grifols (GRFS), Maravai LifeSciences (MRVI), United Therapeutics (UTHR), Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Acerus Pharmaceuticals (ASPCF), Intra-Cellular Therapies (ITCI) and Ascendis Pharma A/S (ASND).
View all of RARE's competitors.

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.53%), Federated Hermes Inc. (5.70%), BlackRock Inc. (4.96%), Wellington Management Group LLP (4.82%), Capital International Investors (4.78%) and Clearbridge Investments LLC (4.10%). Company insiders that own Ultragenyx Pharmaceutical stock include Camille L Bedrosian, Camille L Bedrosian, Clay B Siegall, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski.
View institutional ownership trends for Ultragenyx Pharmaceutical.

Which major investors are selling Ultragenyx Pharmaceutical stock?

RARE stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Invesco Ltd., Bank of New York Mellon Corp, Emerald Mutual Fund Advisers Trust, Capital Group International Inc. CA , BlackRock Inc., Capital International Ltd. CA, and Citigroup Inc.. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Camille L Bedrosian, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, S Robson Walton, Theodore Alan Huizenga, and Thomas Richard Kassberg.
View insider buying and selling activity for Ultragenyx Pharmaceutical or view top insider-selling stocks.

Which major investors are buying Ultragenyx Pharmaceutical stock?

RARE stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, State Street Corp, Rock Springs Capital Management LP, Dimensional Fund Advisors LP, Peregrine Capital Management LLC, International Biotechnology Trust PLC, Verition Fund Management LLC, and Clearbridge Investments LLC.
View insider buying and selling activity for Ultragenyx Pharmaceutical or or view top insider-buying stocks.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $48.55.

How much money does Ultragenyx Pharmaceutical make?

Ultragenyx Pharmaceutical has a market capitalization of $3.40 billion and generates $351.41 million in revenue each year. The biopharmaceutical company earns $-454.02 million in net income (profit) each year or ($6.87) on an earnings per share basis.

How many employees does Ultragenyx Pharmaceutical have?

Ultragenyx Pharmaceutical employs 1,119 workers across the globe.

What is Ultragenyx Pharmaceutical's official website?

The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at [email protected], or via fax at 415-483-8810.